Veracity Capital LLC Sells 2,544 Shares of Avantor, Inc. (NYSE:AVTR)

Veracity Capital LLC decreased its position in Avantor, Inc. (NYSE:AVTR) by 4.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,815 shares of the company’s stock after selling 2,544 shares during the quarter. Veracity Capital LLC’s holdings in Avantor were worth $1,050,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Whalen Wealth Management Inc. bought a new stake in shares of Avantor during the 4th quarter worth $566,000. Nisa Investment Advisors LLC increased its holdings in Avantor by 917.2% during the fourth quarter. Nisa Investment Advisors LLC now owns 20,700 shares of the company’s stock worth $436,000 after buying an additional 18,665 shares during the last quarter. Perpetual Ltd boosted its stake in Avantor by 38.7% in the fourth quarter. Perpetual Ltd now owns 1,766,882 shares of the company’s stock valued at $37,228,000 after acquiring an additional 493,408 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in Avantor by 99.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after acquiring an additional 625 shares during the last quarter. Finally, UMB Bank n.a. grew its position in shares of Avantor by 56.3% during the 4th quarter. UMB Bank n.a. now owns 2,981 shares of the company’s stock valued at $63,000 after acquiring an additional 1,074 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AVTR. UBS Group reissued a “neutral” rating and issued a $25.00 target price (down from $29.00) on shares of Avantor in a research report on Friday, January 17th. Barclays lowered their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Raymond James cut their target price on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research report on Tuesday. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price target on shares of Avantor in a research report on Thursday, September 26th. Finally, Wells Fargo & Company cut their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Avantor currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.38.

Avantor Stock Performance

Shares of NYSE AVTR opened at $21.89 on Friday. The stock has a market cap of $14.90 billion, a price-to-earnings ratio of 47.59, a P/E/G ratio of 3.48 and a beta of 1.28. The stock’s 50-day moving average is $21.46 and its 200 day moving average is $23.39. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. Avantor, Inc. has a 1-year low of $19.59 and a 1-year high of $28.00.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.